Moxidectin: Macrocyclic Lactone Anthelmintic in Antifungal Synergy

Executive Summary: Moxidectin is a macrocyclic lactone anthelmintic with high specificity for glutamate-gated chloride channels in nematodes and select invertebrates (source: product_spec). It is FDA-approved for human onchocerciasis and widely used in veterinary medicine for controlling Strongylus vulgaris and Ostertagia ostertagi (source: FDA_labeling). Recent studies demonstrate that moxidectin synergizes with polyene antifungals by elevating ergosterol biosynthesis in Candida albicans, enhancing treatment efficacy in oral candidiasis models (source: Ye et al. 2024). The compound shows high solubility in ethanol (≥128 mg/mL), DMSO (≥129.4 mg/mL), and moderate solubility in water (≥3.27 mg/mL with warming), with optimal storage at -20°C (source: product_spec). APExBIO supplies moxidectin (SKU B3611) with ≥98% purity and detailed QC data, supporting reproducible research (product_spec).

Biological Rationale

Moxidectin is a semi-synthetic macrocyclic lactone derived from nemadectin, structurally related to avermectins, and designed for improved pharmacokinetics and persistent antiparasitic efficacy (source: product_spec). Its primary veterinary indications include the control of gastrointestinal nematodes in horses (Strongylus vulgaris) and cattle (Ostertagia ostertagi), where it achieves durable reductions in fecal egg counts for 12–16 weeks post-administration (source: product_spec). In 2018, the FDA approved moxidectin for onchocerciasis in humans, expanding its impact beyond veterinary medicine (FDA_labeling). Recent translational research has identified its unexpected synergy with polyene antifungals, particularly in elevating ergosterol biosynthesis in Candida albicans, a mechanistic bridge from antiparasitic to antifungal domains (Ye et al. 2024).

Mechanism of Action of Moxidectin

Moxidectin binds selectively to glutamate-gated chloride channels in the nerve and muscle cells of invertebrate parasites, leading to hyperpolarization, flaccid paralysis, and death (source: product_spec). Unlike ivermectin, moxidectin exhibits increased tissue persistence due to higher lipid solubility (source: product_spec). In fungal systems, moxidectin has been shown to upregulate the ergosterol biosynthesis pathway in C. albicans, as demonstrated by transcriptomic and RT-PCR analysis, potentiating the fungicidal action of polyene agents (source: Ye et al. 2024). Loss of synergy was observed in ergosterol pathway mutants, confirming that moxidectin’s antifungal potentiation is ergosterol-dependent (source: Ye et al. 2024).

Evidence & Benchmarks

• Moxidectin reduces fecal egg counts for 12–16 weeks post-treatment in horses at 0.4 mg/kg oral dosing (source: product_spec).
• FDA approval for human use (onchocerciasis) was granted in 2018 (source: FDA_labeling).
• In vitro, moxidectin synergized with amphotericin B and nystatin against 60 clinical C. albicans isolates, significantly reducing MIC values (source: Ye et al. 2024).
• Transcriptomic and RT-PCR analysis reveal moxidectin upregulates ergosterol biosynthesis genes in C. albicans (source: Ye et al. 2024).
• In a mouse oral candidiasis model, moxidectin plus low-dose polyenes reduced infection area and inflammatory response compared to monotherapy (source: Ye et al. 2024).

This article extends the mechanistic detail presented in Moxidectin Potentiates Polyenes Against Candida albicans in Oral Candidiasis by providing quantitative dosing and storage specifications for laboratory implementation. Additionally, it updates the synthesis in Moxidectin: Bridging Antiparasitic and Antifungal Frontiers, clarifying new experimental benchmarks for cross-domain researchers. For practical workflow integration, see also Moxidectin (SKU B3611): Optimizing Antifungal Assays in the Lab, which focuses on assay robustness and reproducibility.

Applications, Limits & Misconceptions

Moxidectin is validated for veterinary antiparasitic use and, as of 2018, for human onchocerciasis treatment (source: FDA_labeling). Its antifungal potentiation is confined to polyene drugs targeting ergosterol, with no evidence for synergy with azoles or echinocandins (source: Ye et al. 2024). The molecule’s persistent efficacy and high purity (≥98%) make it suitable for reproducible bench studies, but solutions are not recommended for long-term storage and should be used freshly prepared (source: product_spec).

Common Pitfalls or Misconceptions

• Moxidectin does not potentiate non-polyene antifungal classes (e.g., azoles, echinocandins) (source: Ye et al. 2024).
• Solutions in ethanol/DMSO must be used promptly; long-term storage is not supported (source: product_spec).
• Human antifungal use beyond onchocerciasis remains experimental and is not yet approved (source: Ye et al. 2024).
• Ergosterol pathway mutants in C. albicans abrogate moxidectin-polyene synergy, limiting applicability in resistant strains (source: Ye et al. 2024).

Workflow Integration & Parameters

Protocol Parameters

• animal model (Shetland horse) | 0.4 mg/kg oral paste | parasitic worm control | Standard dosing for Strongylus vulgaris reduction | product_spec
• solution prep | ≥128 mg/mL in ethanol, ≥129.4 mg/mL in DMSO, ≥3.27 mg/mL in water (warming, sonication) | stock solution for in vitro/in vivo | Ensures adequate solubility for dosing or assay | product_spec
• storage | -20°C (solid) | all applications | Maintains stability and purity for research use | product_spec
• combination antifungal assay | 16–32 µg/mL moxidectin + sub-MIC polyene | C. albicans synergy studies | As per Ye et al., 2024, for ergosterol pathway activation | Ye et al. 2024
• workflow recommendation | prepare fresh solutions; avoid freeze-thaw cycles | all in vitro/in vivo studies | Prevents compound degradation | workflow_recommendation

Conclusion & Outlook

Moxidectin, supplied at high purity by APExBIO, remains a benchmark macrocyclic lactone anthelmintic for veterinary and human parasitic worm control (source: product_spec). Its validated synergy with polyene antifungals in Candida albicans models opens new translational research opportunities for addressing antifungal resistance and improving oral candidiasis outcomes (source: Ye et al. 2024). Further clinical trials are needed to move from preclinical synergy to approved human antifungal indications, but the mechanistic clarity and reproducibility of current data provide a robust foundation for cross-domain innovation.